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Summary The potential use of human head and neck (H&N) tumours, growing in athymic nude mice, for
preclinical assessment of cytostatic drug sensitivity in a soft agar cloning system was examined. Of 20 H&N
tumour xenografts, obtained from 6 different xenograft lines, 17 demonstrated sufficient colony growth to
evaluate in vitro drug sensitivity. Moreover, all xenografts provided enough cells to test 8 cytostatic drugs at 3
concentrations each. A dose-dependent inhibition of colony growth was obtained with all drugs tested, except
methotrexate. Tumours were considered sensitive when the drug concentration required to inhibit colony
formation by 50%, was less than 1/10 of the peak plasma concentration in patients. All H&N tumour lines
were resistant to cisplatin, doxorubicin, hydroxyurea, mafosfamide (an in vitro active analogue of cyclo-
phosphamide) and methotrexate. Bleomycin was active in 1/6 and 5-fluorouracil in 6/6 of the H&N tumour
lines tested. In 32 cases the in vitro data of the H&N tumour lines and a chemosensitive rat
rhabdomysarcoma were compared directly with in vivo results obtained in nude mice. The clonogenic assay
correctly predicted sensitivity in 4/6 (66.7%) and resistance in 21/26 (80.8%) of the cases. A lack of
correlation was noted for methotrexate, 5-fluorouracil and cyclophosphamide. In vitro culture of human
H&N xenografts may provide a means for a rapid and large scale screening to identify new drugs active
against H&N malignancies. In addition the clonogenic assay may help to select drugs for subsequent testing
in the nude mouse xenograft model. The lack of correlation for some drugs in the present study indicates that
there are some limitations in the use of xenograft tumour material for in vitro testing of new drugs.
There is urgent need for reliable experimental
models in order to improve the chemotherapeutic
treatment of head and neck cancer. Such models
may provide a rationale for the incorporation of
established and new cytostatic agents in clinical
trials.
The nude mouse xenograft model seems suitable
for the evaluation of anticancer drugs. Xenografted
tumours generally respond to agents that are active
in the clinic (Shorthouse et al., 1982; Steel et al.,
1983). Moreover, positive correlations between
chemosensitivity of xenografts and their source
tumours have been described (Nowak et al., 1978;
Osieka, 1984; Fiebig et al., 1984). As a drawback,
in vivo testing with xenografted tumours can be
very time-consuming and expensive.
Soft agar clonogenic assays appear to be
promising in vitro models for chemosensitivity
testing (Tveit et al., 1982; Salmon, 1984). However,
culturing cells obtained from squamous cell
carcinomas of the head and neck (H&N) region
has been rather unsuccessful due to high
contamination rates, small cell yields, low growth
rates and low cloning efficiencies (Johns & Mills,
1983; Mattox et al., 1984; Cobleigh et al., 1984;
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Heinerman et al., 1985). Recently we reported that
79% of head and neck tumours growing in nude
mice could be cultured in the clonogenic assay with
a relatively high cloning efficiency making drug
testing possible (Heinerman et al., 1985). In the
present study we investigated the potential of the
combination of the nude mouse xenograft model
and the clonogenic assay for the selection of
chemotherapeutic agents active against head and
neck cancer.
Materials and methods
Xenografts
Xenografts were grown in female nude mice
(B1O.LP/Cpb, 8-10 weeks old, Centraal
Proefdierenbedrijf TNO, Zeist, the Netherlands).
Tumour specimens from previously untreated
patients were aseptically removed, slices measuring
3 x 3 x 1 mm were dissected and implanted s.c. in
the lateral thoracic region of the test mouse
(Braakhuis et al., 1983). The xenograft HNX-Hep-2
was obtained by s.c. injection of 3 x 106 cells of the
cell line Hep-2 (Gibco), established from a human
squamous cell carcinoma of the larynx (Moore et
al., 1955). In addition, the rat rhabdomyosarcoma
RI was obtained from TNO (Rijswijk, the Nether-
lands) as a solid tumour and xenografted.
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Tumour volume was calculated as length x
width x height x 0.5 (Looney et al., 1973).
Tumours growing in nude mice and measuring 800-
1000mm3 were serially transplanted. The in vitro
and in vivo sensitivity assays were performed within
a maximum of 4 consecutive passages.
Cytostatic drugs
Bleomycin (BLM, Lundbeck), cisplatin (CDDP,
platinol, Bristol Myers), cyclophosphamide (Cy,
ASTA-Werke), doxorubicin hydrochloride (Dox,
adriablastine, Laboratoire Roger Bellon), 5-
fluorouracil (5-FU, Hoffman-La Roche), hydroxy-
urea (Squibb), methotrexate (MTX, Ledertrexate,
Lederle) and vincristine sulfate (VCR, Oncovin, Eli
Lilly) were disolved as indicated by the manu-
facturers. For in vitro experiments drugs were
diluted with saline up to a concentration 10 times
the highest concentration tested and stored by
-20°C. Since Cy is unsuitable for in vitro tests we
used the in vitro active analogue of Cy,
mafosfamide (ASTA Z 7557, ASTA-Werke). This
compound was dissolved in saline immediately
before use.
Clonogenic assay
Tumours were minced into millimeter pieces with
scalpel blades and treated for 2h with 0.2%
collagenase (150Umg-1, type II, Worthington) in
McCoy's 5A medium containing 10% heat
inactivated foetal calf serum (FCS, Gibco), peni-
cillin (10OUml-1) and streptomycin (100ugml-').
Subsequently, the tissue was carefully filtered without
pressure through a 40 mesh wire screen to prepare
a single cell suspension. Cells were cultured in a
bilayer agar system as described by Hamburger and
Salmon (1977), except that no mercaptoethanol and
conditioned medium were added, while horse serum
was replaced by FCS. In brief, the underlayer con-
sisted of enriched McCoy's 5A with 15% FCS and
0.5% agar, the upper layer of enriched CMRL
(Gibco) with 15% FCS and 0.3% agar. Drug
sensitivity assays were performed by continuous
exposure of 3 x 105 cells/plate (H&N cancer
xenografts) or 0.2 x 105 cells/plate (RI tumour) to 3
concentrations of each drug with a 10-log interval.
Drug testing was performed at clinically relevant
concentrations derived from a previous report
(Alberts & Chen, 1980). For Cy the peak plasma
concentration of 4-hydroxy-cyclophosphamide,
the active metabolite of mafosfamide and Cy
(Hilgard & Brock, 1984) was obtained from Voelcker
et al. (1984). Drugs or saline (control plates) were
added immediately before plating. For each experi-
ment 6 control plates were cultured, whereas each
drug concentration was tested in triplicate. Cultures
were incubated at 37°C in a humidified 7.5% Co2
atmosphere. All samples plated were examined by
inverted microscope on day 1 to assure that a
good single cell suspension had been obtained.
Cultures were evaluated after three weeks. The
number of colonies consisting of more than 20 cells
on control and drug treated plates were counted
under the microscope. Plating efficiency was defined
as the number of colonies per plate expressed as a
percentage of the number of cells plated. The
number of clonogenic cells surviving drug treat-
ment was expressed as a percentage of untreated
controls.
In vivo studies
Chemotherapy of tumour xenografts growing sub-
cutaneously in athymic nude mice was performed as
described previously (Braakhuis et al., 1983).
Briefly, chemotherapy was started when, the
tumours reached 100mm3 (range 50-150mm3). The
tumours were randomly divided into treatment and
control groups, each group consisting of at least 5
tumours. Drugs were administered i.p. in a
maximum tolerated dose, i.e. the maximum weight
loss of the mice was 15%. The following schedules
were used: BLM: 15mgkg-1 daily for 3 days,
CDDP: 3mgkg-1 daily for 3-4 days, Dox:
8mgkg' on days 1 and 8, 5-FU: 25mgkg-1 daily
for 4 days, MTX: 5mgkg-1 for 5 days, VCR:
lmgkg-1 daily for 2 days. Growth delay induced
by treatment was defined as the difference between
the mean values of the time required by tumours of
treated and control animals to double their volume,
divided by the mean value of the time needed by
the control mice to double their volume. Growth
delay was thus expressed in terms of the fold
increase in volume doubling time gained by the
treatment. The mean values of doubling times of
control and treated tumours were compared with a
one-way analysis of variance, followed by the
Student-Newman-Keuls-test (Sokal & Rohlf,
1969). Before these tests could be employed the
data were checked for homoscedasticity and
normality.
Results
Xenografts obtained from 6 human head and neck
cancers, 5 squamous cell carcinomas and 1 adenoid
cystic carcinoma, were tested for drug sensitivity in
the clonogenic assay. In addition the rat rhabdo-
myosarcoma RI, maintained as a xenograft in nude
mice, was incorporated in this study. Preliminary
experiments indicated that this tumour is highly
sensitive to chemotherapeutic treatment. The
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500,000 (H&N xenografts) or 3000-50,000 (Ri-
xenograft) resulted in a linear relationship for all
xenografts between the number of cells plated and
the number of colonies formed (data not shown);
for some lines this was reported previously (Heiner-
man et al., 1985). For each xenograft line, three
individual tumours were tested, except for HNX-
HEP-2 where 5 tumours were cultured. In 3
experiments no colony growth was observed
(Table I). In all other experiments the tumours
demonstrated growth of more than 50 colonies per
plate, making evaluation of drug effects possible. A
variation in plating efficiency between tumours of
the same line up to a factor 10 was observed.
Plating efficiencies of the cultured tumour lines
were comparable except for the RI tumour line
which showed about a 10 times higher plating
efficiency.
As shown in Figure 1 a dose-dependent
inhibition of colony growth was observed for all
drugs tested, except for MTX. At the highest MTX
concentration tested (50Mgml -1) there was even
evidence of enhanced colony growth. In vitro
sensitivity of a drug can be expressed in terms of
the ID50, i.e. the concentration required to inhibit
colony formation by 50%. When the ID50 was less
than the clinically relevant level (1/10 peak plasma
concentration), the tumour was considered to be
sensitive. The differences between sensitivities of
individual tumours of the same line were small; the
coefficient of variation (standard deviation divided
by the mean) of the ID50 never exceeded 30%. In
general no marked differences were observed
between the drug sensitivity profiles of the various
H&N tumour lines tested. All lines were resistant
to CDDP, Dox, hydroxyurea, mafosfamide and
MTX. The HNX-FR line was extremely resistant to
CDDP, reflected by a lack of kill at a concentration
of 1 gmlP1. BLM was active in 1 out of 6 and 5-
FU in 6 out of 6 H&N tumour lines tested
(Table II). The RI rat rhabdomyosarcoma was
sensitive to CDDP, Dox, 5-FU, VCR and insensi-
tive to BLM, hydroxyurea, mafosfamide and MTX.
In order to correlate the in vitro and in vivo drug
sensitivity, nude mice bearing xenografted tumours
were treated with the same group of cytostatic
Table I Characteristics of tumour lines
Doubling Successful P.e.d
Linea Histologyb Site timec cultures (range)
HNX-FR mod. diff. scc. hypopharynx 14 2/3 0.047-0.108
HNX-G well diff. scc. skin 15 3/3 0.052-0.148
HNX-GU mod. diff. scc. hypopharynx 16 2/3 0.065-0.130
HNX-HA adenoid cystic ca. oral cavity 19 2/3 0.026-0.292
HNX-Hep-2 poorly diff. scc. larynx 8 5/5 0.019-0.1
HNX-KE poorly diff. scc. larynx 6 3/3 0.036-0.13
Rle rhabdomyosarcoma 4 3/3 0.262-1.269
aHNX: head and neck tumour xenografts; bMod. diff. scc.: moderately differentiated squamous cell
carcinoma; cDoubling time: mean number of days needed by the tumours of a line to grow from 100
to 200mm3; dP.e.: plating efficiencies; CR1: rat rhabdomyosarcoma xenograft.
Table II In vitro sensitivity of tumour xenografts
ID50
Drug 1/10pp.c.a HNX-FR' HNX-G HNX-GU HNX-HA HNX-Hep-2 HNX-KE RJc
BLM 0.2 > 1.0 0.51 0.14 0.22 0.85 0.78 0.33
CDDP 0.2 > 1.0 > 1.0 > 1.0 0.96 0.86 > 1.0 0.14
Dox 0.04 0.075 0.27 0.090 0.065 0.36 0.43 0.026
Hydroxyurea 7.6 36.5 46.2 65.8 54.1 57.0 60.1 34.5
Mafosfamide 0.2 0.50 2.28 0.45 0.73 2.91 0.87 0.60
MTX 0.3 >50.0 >50.0 >50.0 >50.0 >50.0 >50.0 >50.0
VCR 0.01 0.075 0.094 0.35 0.098 0.054 0.58 <<0.01
5-FU 6.0 3.75 1.36 0.81 0.58 4.45 5.56 3.54
Italicized values indicate sensitive tumours, i.e. the IDSO is less than 1/10 of the peak plasma concentration (pgml-1).
al/o p.p.c.: 10% of the peak plasma concentration in patients; 'HNX: head and neck tumour xenograft; CR1: rat
rhabdomyosarcoma xenograft.56 G.H. BOERRIGTER et al.
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Figure 1 Clonogenic cell survival curves for human head and neck cancer cells and the rat
rhabdomyosarcoma (R1) cells plated in soft agar and exposed for 21 days to various cytostatic drugs. V:
HNX-FR, A: HNX-G, 0: HNX-GU, 0: HNX-HA, *: HNX-Hep-2, Ol: HNX-KE, *: RI. Each point
represents the mean of 2-5 individual experiments as indicated in Table I.
drugs. Up to now we were able to test 6 xenograft
lines with 3 to 7 drugs in vivo (Table III). With
respect to the head and neck xenografts in 10 out
of 25 experiments a significant growth delay was
induced. When a growth delay exceeding 2 was
taken as an activity criterion, as proposed by
Osieka (1984) and Tveit et al. (1982), only 1 H &N
tumour line responded to treatment (HNX-GU to
BLM). The RI tumour line was found to be
sensitive to all drugs tested, except to 5-FU and
BLM.
Analysis of correlation between in vivo and in
vitro activity is shown in Table IV. With the chosen
'cut-off' points the in vitro data predicted correctly
the in vivo results for BLM, CDDP, Dox and VCR.
HNX-FR was found the most resistant line to
CDDP in vivo as well as in vitro. For three drugs
the in vitro results did not correlate. Sensitivity in
vitro for 5-FU was detected in 5 lines; in vivo,
however, none of these lines showed a response. All
tumour lines were insensitive to mafosfamide and
MTX in vitro, while in vivo only the Rl tumour
was sensitive to these drugs. The overall predictive
value of the in vitro system for sensitivity was 4/6
(66.7%); and for resistance, 21/26 (80.8%).
Discussion
Human head and neck cancers, transplanted and
growing in athymic nude mice can be cultured in
the clonogenic assay with a high success rate. This
is in sharp contrast to head and neck tumours
obtained directly from patients where small yields,
low growth rates, low cloning efficiencies and high
contamination rates limits the applicability of the
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Table III In vivo sensitivity of tumour xenografts
Drug HNX_FRa HNX-G HNX-GU HNX-Hep-2 HNX-KE Rlb
BLM 0.8 0.4 2.6 0.4 0.4 1.2 (0/6)C
CDDP 1.0 1.4 nt 1.6 1.5 2.4 (1/5)
Cy 0.2 1.9 nt 0.4 1.0 5.4 (6/7)
Dox nt nt nt 0.6 0.4 5.8 (3/9)
MTX 0.0 1.6 0.1 nt 0.3 3.3 (1/9)
VCR nt 0.6 nt nt 0.5 3.5 (5/7)
5-FU 1.0 0.4 0.9 nt 1.0 0.7 (0/8)
In vivo sensitivity is expressed as growth delay. For the computation of growth delay and
the treatment schedules: see Materials and methods. Statistical significant growth delays are
italicized.
aHNX: head and neck tumour xenograft; bRl: rat rhabdomyosarcoma xenograft; cIn
parentheses: the number of completely regressed tumours divided by the number of treated
tumours; nt: not tested.
Table IV Correlation between in vitro and in vivo
response
Drug S/Se R/S S/R R/R Total
BLM 1 5 6
CDDP 1 4 5
Dox 1 2 3
Mafosfamide/Cy 1 4 5
MTX 1 4 5
VCR 1 2 3
5-FU 5 5
Total 4 2 5 21 32
The criterion for sensitivity was for (a) in vitro:
ID50 < 1/10 of the peak plasma concentration and (b) in
vivo: growth delay>2.0. Predictive value of in vivo sensi-
tivity: 4/6 (66.7%). Predictive value of in vivo resistance:
21/26 (80.8%).
as sensitive, R: resistant (in vitro/in vivo).
clonogenic assay for drug sensitivity studies
(Johns & Mills, 1983; Mattox et al., 1984; Cobleigh
et al., 1984; Heinerman et al., 1985). Moreover, as
illustrated in the present study, xenografts provide
enough cells to test at least 24 drugs or drug
concentrations, and drug testing can be repeated.
An inhibition of more than 50% by continuous
exposure of 1/10 of the peak plasma concentration
was observed in 7 out of 48 (14.6%) of the head
and neck cancers. This is in agreement with results
obtained with tumours from various sites, taken
directly from patients (Bertelsen et al., 1984; Von
Hoff et al., 1983; Shoemaker et al., 1985).
In vivo treatment of head and neck tumour
bearing nude mice showed that growth of all xeno-
graft lines tested could be delayed by at least one
anticancer drug. However, except for 1 head and
neck tumour line, highly sensitive to treatment with
BLM, a growth delay exceeding 2 was never
observed.
In order to avoid extensive time-consuming in
vivo testing, the clonogenic assay might be helpful
to select potentially active drugs for H&N cancer.
To use this assay for drug screening it is important
to know whether the in vitro results correctly
predict the in vivo results. Based on our experiments
the clonogenic assay would have correctly predicted
sensitivity in 4 out of 6 (66.7%) and resistance in
21/26 (80.8%) of the cases. For BLM, CDDP,
VCR and Dox the overall correlation was 100%,
although for the two latter drugs only 3
correlations could be made. Positive correlations
between drug sensitivity and resistance of human
tumour xenografts in the nude mouse xenograft58 G.H. BOERRIGTER et al.
model and the clonogenic assay have been reported
previously (Bateman et al., 1980; Taetle et al., 1982;
Tveit et al., 1980; Zirvi et al., 1983; Friedman et al.,
1984). However, for Dox, the in vitro activity was
not reflected by an in vivo delay of tumour growth
(Bateman et al., 1980), which is not in agreement
with the results of Taetle et al. (1982) and those
reported in this paper. Also for some analogues of
Dox a significant negative correlation between the
results in the clonogenic assay and nude mice was
reported (Taetle et al., 1982).
A number of problems are associated with in
vivo-in vitro correlations (Selby et al., 1983; Single-
tary et al., 1985; Twentyman, 1985). Growth delay
in vivo depends upon the cytostatic drug dose, the
schedule of treatment as well as the pharmaco-
kinetics in nude mice. Moreover, growth delay may
not only reflect kill of clonogenic cells but also of
other tumour cells and non-tumour cells. On the
other hand, inhibition of colony growth depends on
the drug concentration, the exposure time and
stability of drugs in vitro. The lack of correlation
between in vivo and in vitro sensitivity in the present
study for Cy (RI tumour) and 5-FU (all tumour
lines) may be connected with the above mentioned
problems. In addition, the complete ineffectiveness
of 5-FU in the nude mouse model may well be
related to a relatively low peak plasma level in this
species as compared to the human situation (Inaba
et al., 1984). The ineffectiveness of MTX in vitro in
the present study may be due to the presence of
nucleobases in the culture media (Umbach et al.,
1984). Indeed we recently found for the MTX-
sensitive RI tumour that a complete inhibition of
colony growth could be obtained at a concentration
of 0.05jugMTXml-1 by using nucleoside-free
culture media and dialysed fetal bovine serum
(unpublished results).
A number of problems have to be solved before
the clonogenic assay can be applied to predict the
sensitivity of an individual patient's tumour (Von
Hoff et al., 1984). Recently it was reported that this
system may play a useful additional role in the
testing of new drugs (Shoemaker et al., 1985). The
use of xenografts as a tumour source gives some
advantages over the use of patient's tumours. The
plating efficiencies are higher in xenografts than in
patient's tumours, especially for H&N cancer
(Heinerman et al., 1985). With xenografts drug
testing can be reproducible, repeated and can be
related directly to in vivo testing in the nude mouse.
The clonogenic assay can be used to select new
drugs for subsequent testing in the nude mouse.
Our results with established drugs indicate that the
clonogenic assay predicted sensitivity and resistance
in a majority of cases. Due to the lack of
correlation between in vitro and in vivo sensitivity
for some drugs, one has to be aware that combina-
tion of these models will have limitations, when it is
used in the screening of new drugs.
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